|
|
|
REGIMEN: CALG-B(LARSON)(INDUCTION)
CYCLOPHOSPHAMIDE [CTX] 1200 mg/m2 IV...D1
DAUNORUBICIN [DNR] 45 mg/m2 per
day IV...D1-3
Caution: Monitor cumulative dose (cardiac toxicity)
VINCRISTINE [VCR] 2 mg
IV...D1,8,15,22
Maximum dose is 2 mg
PREDNISONE [Pred] 60 mg/m2 per day PO...D1-21
L-ASPARAGINASE [A-ase] 6000 units/m2 IV...D5,8,11,15,18,22
CYCLE: None
REFER: Larson RA, et al: PROC ASCO 1992; 11:263.
DISEASE: Chronic Lymphocytic
REGIMEN: CP
CHLORAMBUCIL [Chl]
.4 mg/kg PO...D1
q other wk
PREDNISONE [Pred] 100 mg per day
PO...D1-7
q other wk
CYCLE: None
REFER: Leukeran (R) (chlorambucil) Tablets, Burroughs Wellcome Co., full
prescribing info, PHYSICIANS DESK REFERENCE 49th Ed. Montvale,NJ; 1995;781.
DISEASE: Chronic Lymphocytic
REGIMEN: CVP-2
CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 per day PO...D1-5
VINCRISTINE [VCR] 2 mg/m2 IV...D1
Maximum dose is 2 mg
PREDNISONE [Pred] 100 mg/m2 per day PO...D1-5
CYCLE: 21 - 28 days
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown &
Co. 1991; 319.
DISEASE: Chronic Lymphocytic
REGIMEN: FAMP
FLUDARABINE [FLUD]
25 - 30 mg/m2 per day IV/30 min...D1-5
Over 30 minutes
CYCLE: 4 wks
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown &
Co. 1991; 110.
DISEASE: Acute Myelogenous
REGIMEN: A+D(7+3)(INDUCTION)
CYTARABINE [ARA-C] 100 mg/m2 per day x 7 CIV...D1-7
DAUNORUBICIN [DNR] 45 mg/m2 per
day IV...D1-3
Caution: Monitor cumulative dose (cardiac toxicity) Note: Repeat for further
induction or consolidation with cytarabine x 5 days and daunorubicin x 2 days
CYCLE: None
REFER: Dillman RO, et al: BLOOD 1991; 78:2520-2526.
DISEASE: Acute Myelogenous
REGIMEN: A+D+E(7+3+7)(INDUCTION)
CYTARABINE [ARA-C] 100 mg/m2 per day CIV...D1-7
DAUNORUBICIN [DNR] 50 mg/m2 per
day IV...D1-3
Caution: Monitor cumulative dose (cardiac toxicity)
ETOPOSIDE [VP-16] 75 mg/m2 per day IV/1 hr...D1-7
CYCLE: Induction
REFER: Bishop J, et al: BLOOD 1990; 1/1 75(1):27-32.
DISEASE: Acute Myelogenous
REGIMEN: HiDAC
CYTARABINE [ARA-C]
1.5 - 3 g/m2 IV/12 h
x 4-6 days
CYCLE: None
REFER: Bloomfield CD, Herzig GP, eds.: HEMATOLOGY/ONCOLOGY CLINICS OF NORTH
AMERICA 1993; 7:47-79.
DISEASE: Acute Myelogenous
REGIMEN: IDA-AR 1 (INDUCTION)
IDARUBICIN
[IDA] 12 mg/m2 per day IV...D1-3
Caution: Monitor cumulative dose (cardiac toxicity)
CYTARABINE [ARA-C] 100 mg/m2 per day x 7 CIV...D1-7
CYCLE: None
REFER: Vogler WR, et al: J CLIN ONCOL 1992; 10:1103-1111.
DISEASE: Acute Myelogenous
REGIMEN: IDA-AR 2 (CONSOLIDATION)
THIOGUANINE
[6-TG] 100 mg/m2 PO q 12h
x 10 doses
CYTARABINE [ARA-C] 100 mg/m2 IV q
12h
x 10 doses
IDARUBICIN [IDA] 15 mg/m2 IV...D1
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLE: 21-28 days x 3 courses
REFER: Vogler WR, et al: J CLIN ONCOL 1992; 10:1103-1111.
DISEASE: Acute Myelogenous
REGIMEN: MC (INDUCTION)
MITOXANTRONE [DHAD]
12 mg/m2 per day IV...D1-3
Caution: Monitor cumulative dose (cardiac toxicity)
CYTARABINE [ARA-C] 100 mg/m2 per day x 7 CIV...D1-7
CYCLE: Induction
REFER: Arlin Z, et al: LEUKEMIA 1990; 4:177-183.
DISEASE: Chronic Myelogenous
REGIMEN: BUSULFAN
BUSULFAN [BU] 4 - 8 mg PO q d
CYCLE: None
REFER: Myleran (R) (busulfan) Burroughs Wellcome Co, full prescribing info in
PHYSICIANS DESK REFERENCE 49th Ed. Montvale,NJ; 1995;781.
DISEASE: Chronic Myelogenous
REGIMEN: HYDROXYUREA
HYDROXYUREA [HU] .5 - 1.5 g/m2 PO/d
CYCLE: None
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown &
Co. 1991; 313.
DISEASE: Chronic Myelogenous
REGIMEN: IFN-a
IFN-alpha [IFN-a] 5 MU/m2 per day IM
CYCLE: None
REFER: Talpaz M, et al: NEJM 1986; 314:1065-1069.
DISEASE: Lymphona: Hodgkins
REGIMEN: ABVD
DOXORUBICIN [DOX] 25 mg/m2 IV...D1,14
Caution: Monitor cumulative dose (cardiac toxicity)
BLEOMYCIN [BLEO] 10 units/m2 IV...D1,14
Caution: Monitor cumulative dose (pulmonary toxicity)
VINBLASTINE [VLB] 6 mg/m2 IV...D1,14
DACARBAZINE [DTIC] 150 mg/m2 IV... D1-5
CYCLE: 28 days for 6 cycles
REFER: Bonadonna G, et al: CANCER 1975; 36:252-259.
DISEASE: Lymphoma: Hodgkin's
REGIMEN: BCVPP
CARMUSTINE [BCNU] 100 mg/m2 IV... D1
Caution: Monitor cumulative dose (pulmonary and marrow toxicity)
VINBLASTINE [VLB] 5 mg/m2 IV... D1
CYCLOPHOSPHAMIDE [CTX] 600 mg/m2 IV... D1
PROCARBAZINE [PCB] 50 mg/m2 PO... D1
1st day only
PROCARBAZINE [PCB] 100 mg/m2 per day PO... D2-10
After 1st day
PREDNISONE[Pred] 60 mg/m2 per day PO... D1-10
CYCLE: 28 days
REFER: Bakemeier RF, et al: ANN INTERN MED 1984; 101:447-456.
DISEASE: Lymphoma: Hodgkin's
REGIMEN: EVA
ETOPOSIDE [VP-16] 100 mg/m2 per day IV... D1-3
VINBLASTINE [VLB] 6 mg/m2 IV... D1
DOXORUBICIN [DOX] 50 mg/m2 IV...
D1
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLE: 28 days for 6 cycles
REFER: Canellos GP, et al: PROC ASCO 1991; 10:273.
DISEASE: Lymphoma: Hodgkin's
REGIMEN: MOPP
MECHLORETHAMINE [HN(2)] 6 mg/m2 IV... D1,8
VINCRISTINE [VCR] 1.4 mg/m2 IV...
D1,8
(No cap at 2 mg)
PROCARBAZINE [PCB] 100 mg/m2 per day PO... D1-14
PREDNISONE [Pred] 40 mg/m2 per day PO... D1-14
CYCLE: 28 days
REFER: DeVita VT, et al: PPO UPDATES 1993; 7:1-11.
DISEASE: Lymphoma: Hodgkin's
REGIMEN: MOPP/ABV
MECHLORETHAMINE [HN(2)] 6 mg/m2 IV... D1
VINCRISTINE [VCR] 1.4 mg/m2 IV... D1
PROCARBAZINE [PCB] 100 mg/m2 per day PO... D1-7
PREDNISONE [Pred] 40 mg/m2 per day PO... D1-14
DOXORUBICIN [DOX] 35 mg/m2 IV...
D8
Caution: Monitor cumulative dose (cardiac toxicity)
BLEOMYCIN [BLEO] 10 units/m2
IV... D8
Caution: Monitor cumulative dose (pulmonary toxicity)
VINBLASTINE [VLB] 6 mg/m2 IV... D8
CYCLE: 28 days
REFER: Connors JM, et al: PROC ASCO 1992; 11:317.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: CHOP
CYCLOPHOSPHAMIDE [CTX] 750 mg/m2 IV... D1
DOXORUBICIN [DOX] 50 mg/m2 IV...
D1
Caution: Monitor cumulative dose (cardiac toxicity)
VINCRISTINE [VCR] 1.4 mg/m2 IV...
D1
Maximum dose is 2 mg
PREDNISONE [Pred] 100 mg per day PO... D1-5
CYCLE: 21 days
REFER: Skeel RT: Handbook of Cancer Chemotherapy, 3rd Ed. Little, Brown &
Co. 1991; 343.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: CHOP-BLEO
CYCLOPHOSPHAMIDE [CTX] 750 mg/m2 IV... D1
DOXORUBICIN [DOX] 50 mg/m2 IV...
D1
Caution: Monitor cumulative dose (cardiac toxicity)
VINCRISTINE [VCR] 2 mg IV... D1,5
Maximum dose is 2 mg
PREDNISONE [Pred] 100 mg per day PO... D1-5
BLEOMYCIN [BLEO] 15 units per day
IV... D1-5
Caution: Monitor cumulative dose (pulmonary toxicity)
CYCLE: 14 or 21 days
REFER: Rodriguez V, et al: BLOOD 1977; 49:325-333.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: COMLA
CYCLOPHOSPHAMIDE [CTX] 1500 mg/m2 IV... D1
VINCRISTINE [VCR] 1.4 mg/m2 IV...
D1,8,15
Maximum dose is 2 mg
METHOTREXATE [MTX] 120 mg/m2 IV... D22,29,36,43,50,57,64,71
LEUCOVORIN [Leu] 25 mg/m2 PO...
D23,30,37,44,51,58,65,72
q6h x 4 doses beginning 24 hr post MTX
CYTARABINE [ARA-C] 300 mg/m2 IV... D22,29,36,43,50,57,64,71
CYCLE: 91 days
REFER: Gaynor ER, et al: J CLIN ONCOL 1985; 3:1596-1604.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: COP
CYCLOPHOSPHAMIDE [CTX] 400 - 800 mg/m2 IV... D1
VINCRISTINE [VCR] 2 mg IV... D1
Maximum dose is 2 mg
PREDNISONE [Pred] 60 mg/m2 per
day PO... D1-5
Followed by tapering dose 40,20,10 mg/day
CYCLE: 14 days
REFER: Luce JK, et al: CANCER 1971; 28:306-317.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: CVP-1
CYCLOPHOSPHAMIDE [CTX] 400 mg/m2 per day PO... D1-5
VINCRISTINE [VCR] 1.4 mg/m2 IV...
D1
Maximum dose is 2 mg
PREDNISONE [Pred] 100 mg/m2 per day PO... D1-5
CYCLE: 21 days
REFER: Bagley CM, et al: ANN INTERN MED 1972; 76:227-234.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: DHAP
CISPLATIN [CDDP] 100 mg/m2 CIV over 24 hrs... D1
CYTARABINE [ARA-C] 2 g/m2 IV over
3 hrs... D2
After Cisplatin repeat dose 12 hrs later for total dose of 4 g/m2
DEXAMETHASONE [DEX] 40 mg per day
PO or IV... D1-4
For 4 days
CYCLE: 3-4 weeks
REFER: Velasquez WS, et al: BLOOD 1988; 71:117-122.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: ESAP
METHYLPREDNISOLONE[SOL] 500 mg per day IV... D1-4
ETOPOSIDE [VP-16] 40 mg/m2 per day IV... D1-4
CYTARABINE [ARA-C] 2 g/m2 IV...
D5
Over 2 hr, after completion of Cisplatin
CISPLATIN [CDDP] 25 mg/m2 per day
x 4 CIV... D1-4
(Total Dose 100 mg)
CYCLE: As tolerated
REFER: Velasquez W, et al: PROC ASCO 1989; 8:256.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: MACOP-B
METHOTREXATE [MTX] 400 mg/m2 IV... weeks 2,6,10
LEUCOVORIN [Leu] 15 mg PO
q 6 hr x 6 doses, starting 24hr after MTX
DOXORUBICIN [DOX] 50 mg/m2 IV...
weeks 1,3,5,7,9,11
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLOPHOSPHAMIDE [CTX] 350 mg/m2 IV... weeks 1,3,5,7,9,11
VINCRISTINE [VCR] 1.4 mg/m2 IV...
weeks 2,4,6,8,10,12
Max dose 2mg
BLEOMYCIN [BLEO] 10 units/m2
IV... weeks 4,8,12
Caution: Monitor cumulative dose (pulmonary toxicity)
PREDNISONE [Pred] 75 mg per day
PO
Tapered over last 15 days
CYCLE: None
REFER: Connors JM, et al (eds). Update on Treatment for Diffuse Large Cell
Lymphoma. Wiley & Sons 1986; 37-43.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: MIV
MITOXANTRONE [DHAD]
10 mg/m2 IV... D1
Caution: Monitor cumulative dose (cardiac toxicity)
IFOSFAMIDE [IFF] 1500 mg/m2 per
day IV... D1-3
With MESNA
ETOPOSIDE [VP-16] 150 mg/m2 per day IV... D1-3
CYCLE: 21 days
REFER: Herbrecht R, et al: PROC ASCO 1991; 10:278.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: m-BACOD
METHOTREXATE [MTX] 200 mg/m2 IV... D8,15
LEUCOVORIN [Leu] 10 mg/m2 PO...
D9,16
q6h x 8 doses starting 24h after MTX
BLEOMYCIN [BLEO] 4 units/m2 IV...
D1
Caution: Monitor cumulative dose (pulmonary toxicity)
DOXORUBICIN [DOX] 45 mg/m2 IV...
D1
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLOPHOSPHAMIDE [CTX] 600 mg/m2 IV... D1
VINCRISTINE [VCR] 1 mg/m2 IV...
D1
Maximum dose is 2 mg
DEXAMETHASONE [DEX] 6 mg/m2 per day PO... D1-5
CYCLE: 3 Wks.
REFER: Shipp MA, et al: ANN INTERN MED 1986; 104:757-765.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: PROMACE-CYTABOM
PREDNISONE [Pred] 60 mg/m2 per day PO... D1-14
DOXORUBICIN [DOX] 25 mg/m2 IV...
D1
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLOPHOSPHAMIDE [CTX] 650 mg/m2 IV... D1
ETOPOSIDE [VP-16] 120 mg/m2 IV... D1
CYTARABINE [ARA-C] 300 mg/m2 IV... D8
BLEOMYCIN [BLEO] 5 units/m2 IV...
D8
Caution: Monitor cumulative dose (pulmonary toxicity)
VINCRISTINE [VCR] 1.4 mg/m2 IV...
D8
Maximum dose is 2 mg
METHOTREXATE [MTX] 120 mg/m2 IV... D8
LEUCOVORIN [Leu] 25 mg PO... D9
q6h x 4 doses starting 24 hrs after MTX
CYCLE: 21 days, next cycle begins on D22
REFER: Fisher RI, et al: PROC ASCO 1984; 242. Abstract.
DISEASE: Lymphoma: Non Hodgkin's
REGIMEN: VACOP-B
ETOPOSIDE
[VP-16] 50 mg/m2 IV... D1
And 100 mg/m2 per day PO D2,3 of week 3,7,11
DOXORUBICIN [DOX] 50 mg/m2 IV...
weeks 1,3,5,7,9,11
Caution: Monitor cumulative dose (cardiac toxicity)
CYCLOPHOSPHAMIDE [CTX] 350 mg/m2 IV... weeks 1,5,9
VINCRISTINE [VCR] 1.2 mg/m2 IV...
weeks 2,4,6,8,10,12
No maximum vincristine dose
PREDNISONE [Pred] 45 mg/m2 PO... q Dx1 week, then q OD x 11 wks
BLEOMYCIN [BLEO] 10 units/m2
IV... weeks 2,4,6,8,10,12
Caution: Monitor cumulative dose (pulmonary toxicity)
CYCLE: None
REFER: Connors JM, et al: PROC ASCO 1990; 9:254.
DISEASE: Multiple Myeloma
REGIMEN: DEXA
DEXAMETHASONE [DEX] 40 mg per day PO... D1-4,9-12,17-20
CYCLE: 36 days
REFER: Alexanian R: ANN INTERN MED 1986; 105:8-11.
DISEASE: Multiple Myeloma
REGIMEN: MP1
MELPHALAN [L-Pam] .15 mg/kg per day PO... D1-7
PREDNISONE [Pred] 20 mg TID PO... D1-7
CYCLE: 6 weeks
REFER: Kyle RA, Greipp PA: CRC CRIT REV ONCOL/HEMATOL 1988; 8:93-152.
DISEASE: Multiple Myeloma
REGIMEN: MP 2
MELPHALAN [L-Pam] .25 mg/kg per day PO... D1-4
PREDNISONE [Pred] 2 mg/kg per day PO... D1-4
CYCLE: 6 weeks
REFER: Alkeran (R) (melphalan) Tablets, Burroughs Wellcome Co, full prescribing
info in PHYSICIANS DESK REFERENCE 49th Ed. Montvale,NJ; 1995;746.
DISEASE: Multiple Myeloma
REGIMEN: MP 3
MELPHALAN
[L-Pam] 16 mg/m2 per day IV
Every 2 weeks for 4 doses, then every 4 weeks
PREDNISONE [Pred] .8 mg/kg per
day PO... D1-14
Maximum dose is 100 mg/day
PREDNISONE [Pred] .4 mg/kg per
day PO... D15-28
Maximum dose is 100 mg/day
PREDNISONE [Pred] .2 mg/kg per
day PO... D29-42
Maximum dose is 100 mg/day
CYCLE: None
REFER: Cooper MR, et al: J CLIN ONCOL 1986; 4(9):1331 - 1339.
DISEASE: Multiple Myeloma
REGIMEN: VAD
VINCRISTINE
[VCR] .4 mg per day x 4 CIV... D1-4
Maximum dose is 2 mg
DOXORUBICIN [DOX] 9 mg/m2 per day
x 4 CIV... D1-4
Caution: Monitor cumulative dose (cardiac toxicity)
DEXAMETHASONE [DEX] 40 mg per day PO... D1-4,9-12,17-20
CYCLE: 28 days
REFER: Barlogie B, et al: NEJM 1984; 310:1353-1356.
Body Surface Area (in meters squared )
BSA = 0.007184 x [Weight in kg] to power 0.425 x [Height in cm] to power 0.725
(Dubois, Arch Intern Med 1916; 17:863-871)
Ideal Body Weight [in kg]
For Males
IBW = 51.65 + 1.85 x ([Height in inches] - 60)
For Females
IBW = 48.67 + 1.65 x ([Height in inches] - 60)
(Am J Hosp Pharm 1983; 40(6):1016-1019)
Basic Energy Expenditure [in KCal/day]
For Males
BEE = 66 + 13.7 x [Weight in kg] + 5.0 x [Height in cm] - 6.8 x Age
For Females
BEE = 655 + 9.6 x [Weight in kg] + 1.8 x [Height in cm] - 4.7 x Age
(Wilson JD, et al: Harrison's Principles of Internal Medicine, 12th Ed. McGraw-Hill 1991; 430)
Absolute Neutrophil Count [in K/mm3]
ANC = [WBC in K/mm3] x ( [PMN in %] + [Bands in %] ) / 100
Estimated Creatinine Clearance [in cc/min]
For Males
CCr = [Weight in kg] x ( 140 - Age ) / (72 x SerumCreatinine)
For Females
CCr = [Male Est CCr] x 0.85
Serum Creatinine measured in mg/dL
(Cockroft DW, Gault MH: NEPHRON 1976; 16:31-41)
Measured Creatinine Clearance (in cc/min]
CCr = (UrineCreatinine x UrineVolume)/(1440 x SerumCreatinine)
Serum Creatinine measured in mg/dL
Urine Creatinine measured in mg/dL
Urine Volume measured in mL/24 hrs
(Comstock,TJ. Pharmaco Therapy; Elsevier 1992:645-659)